Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-Completed study UBR-MD-01(NCT02828020) or UBR-MD-02(NCT02867709).~Exclusion Criteria:~* Patients with clinically significant electrocardiogram (ECG), vital sign, physical exam, or laboratory abnormalities~* Requirement for a medication during the study that is on the list of prohibited medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: ACTIVE_COMPARATOR): Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
- Ubrogepant 50 mg (Type: EXPERIMENTAL): Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
- Ubrogepant 100 mg (Type: EXPERIMENTAL): Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.

Based on this trial design, predict the completion outcome and termination type (if applicable).